Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome

被引:864
作者
Lang, GA
Iwakuma, T
Suh, YA
Liu, G
Rao, VA
Parant, JM
Valentin-Vega, YA
Terzian, T
Caldwell, LC
Strong, LC
El-Naggar, AK
Lozano, G
机构
[1] Univ Texas, Grad Sch Biomed Sci, Dept Mol Genet, Sect Canc Genet, Houston, TX 77030 USA
[2] Univ Texas, Grad Sch Biomed Sci, Dept Expt Therapeut, Houston, TX 77030 USA
[3] Univ Texas, Grad Sch Biomed Sci, Dept Pathol, Houston, TX 77030 USA
关键词
D O I
10.1016/j.cell.2004.11.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Individuals with Li-Fraumeni syndrome carry inherited mutations in the p53 tumor suppressor gene and are predisposed to tumor development. To examine the mechanistic nature of these p53 missense mutations, we generated mice harboring a G-to-A substitution at nucleotide 515 of p53 (p53(+/515A)) corresponding to the p53R175H hot spot mutation in human cancers. Although p53(+/515A) mice display a similar tumor spectrum and survival curve as p53(+/-) mice, tumors from p53(+/515A) mice metastasized with high frequency. Correspondingly, the embryonic fibroblasts from the p53(515A/515A) mutant mice displayed enhanced cell proliferation, DNA synthesis, and transformation potential. The disruption of p63 and p73 in p53(-/-) cells increased transformation capacity and reinitiated DNA synthesis to levels observed in p53(515A/515A) cells. Additionally, p63 and p73 were functionally inactivated in p53(515A) cells. These results provide in vivo validation for the gain-of-function properties of certain p53 missense mutations and suggest a mechanistic basis for these phenotypes.
引用
收藏
页码:861 / 872
页数:12
相关论文
共 65 条
[1]   Post-translational modifications and activation of p53 by genotoxic stresses [J].
Appella, E ;
Anderson, CW .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2001, 268 (10) :2764-2772
[2]   p53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1 [J].
Asher, G ;
Lotem, J ;
Tsvetkov, P ;
Reiss, V ;
Sachs, L ;
Shaul, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (25) :15065-15070
[3]  
BARTEK J, 1991, ONCOGENE, V6, P1699
[4]  
Bataille F, 2003, J CLIN PATHOL-MOL PA, V56, P286
[5]   TP53 family members and human cancers [J].
Bénard, J ;
Douc-Rasy, S ;
Ahomadegbe, JC .
HUMAN MUTATION, 2003, 21 (03) :182-191
[6]   GENETIC MECHANISMS OF TUMOR SUPPRESSION BY THE HUMAN P53 GENE [J].
CHEN, PL ;
CHEN, YM ;
BOOKSTEIN, R ;
LEE, WH .
SCIENCE, 1990, 250 (4987) :1576-1580
[7]   Transdominant ΔTAp73 isoforms are frequently up-regulated in ovarian cancer.: Evidence for their role as epigenetic p53 inhibitors in vivo [J].
Concin, N ;
Becker, K ;
Slade, N ;
Erster, S ;
Mueller-Holzner, E ;
Ulmer, H ;
Daxenbichler, G ;
Zeimet, A ;
Zeillinger, R ;
Marth, C ;
Moll, UM .
CANCER RESEARCH, 2004, 64 (07) :2449-2460
[8]   Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function [J].
de Vries, A ;
Flores, ER ;
Miranda, B ;
Hsieh, HM ;
van Oostrom, CTM ;
Sage, J ;
Jacks, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) :2948-2953
[9]  
Di Como CJ, 1999, MOL CELL BIOL, V19, P1438
[10]   GAIN OF FUNCTION MUTATIONS IN P53 [J].
DITTMER, D ;
PATI, S ;
ZAMBETTI, G ;
CHU, S ;
TERESKY, AK ;
MOORE, M ;
FINLAY, C ;
LEVINE, AJ .
NATURE GENETICS, 1993, 4 (01) :42-46